- Home
- RSVR vs CVAC Comparison
RSVR vs CVAC Comparison
Compare RSVR & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSVR
- CVAC
- Stock Information
- Founded
- RSVR 2007
- CVAC 2000
- Country
- RSVR United States
- CVAC Germany
- Employees
- RSVR N/A
- CVAC N/A
- Industry
- RSVR Movies/Entertainment
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- RSVR Consumer Discretionary
- CVAC Health Care
- Exchange
- RSVR Nasdaq
- CVAC Nasdaq
- Market Cap
- RSVR 504.1M
- CVAC 1.2B
- IPO Year
- RSVR N/A
- CVAC 2020
- Fundamental
- Price
- RSVR $7.92
- CVAC $5.36
- Analyst Decision
- RSVR Strong Buy
- CVAC Hold
- Analyst Count
- RSVR 1
- CVAC 3
- Target Price
- RSVR $11.50
- CVAC $6.83
- AVG Volume (30 Days)
- RSVR 54.3K
- CVAC 475.8K
- Earning Date
- RSVR 10-29-2025
- CVAC 11-11-2025
- Dividend Yield
- RSVR N/A
- CVAC N/A
- EPS Growth
- RSVR N/A
- CVAC N/A
- EPS
- RSVR 0.12
- CVAC 1.01
- Revenue
- RSVR $161,553,186.00
- CVAC $599,540,810.00
- Revenue This Year
- RSVR $7.17
- CVAC N/A
- Revenue Next Year
- RSVR $5.00
- CVAC $23.95
- P/E Ratio
- RSVR $68.02
- CVAC $5.32
- Revenue Growth
- RSVR 9.65
- CVAC 675.15
- 52 Week Low
- RSVR $6.56
- CVAC $2.37
- 52 Week High
- RSVR $9.83
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- RSVR 53.34
- CVAC 45.55
- Support Level
- RSVR $7.65
- CVAC $5.34
- Resistance Level
- RSVR $8.08
- CVAC $5.41
- Average True Range (ATR)
- RSVR 0.18
- CVAC 0.04
- MACD
- RSVR -0.01
- CVAC -0.00
- Stochastic Oscillator
- RSVR 63.53
- CVAC 39.44
About RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. It operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the Music Publishing segment.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.